Company / Cash & Equivalents
Cullinan Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$83.0M
FY2024
5-year range
$59.8M / $168.2M
FY2020-FY2024
Trend
-15.7%
vs FY2023
Sector context
#157 of 207
Health Care
What the data says
Cullinan Therapeutics, Inc.'s cash & equivalents of $83M is lower than 76% of companies in the Health Care sector (FY2024). Declined from $156M to $83M over the past 2 years.
Based on SEC 10-K filings.
$83M in FY2024 with a 3-year CAGR of +11.6%.
Declined from $156M to $83M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +11.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 207This company $83.0M Sector average $669.5M
▼
-87.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +11.6%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 15.7% year-over-year.
- Ranks #157 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $83.0M | -15.7% |
| FY2023 | $98.4M | -37.0% |
| FY2022 | $156.2M | +161.2% |
| FY2021 | $59.8M | -64.5% |
| FY2020 | $168.2M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026